Brief: Genelux Corp Announces Interim Results From Ongoing Lung Cancer Trials
05/01/2026 14:01
Jan 5 (Reuters) - Genelux Corp GNLX.O: GENELUX CORP - ANNOUNCES INTERIM RESULTS FROM ONGOING LUNG CANCER TRIALS GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25) GENELUX CORP - TOPLINE DATA FROM PHASE 3 OVARIAN CANCER TRIAL (ONPRIME/GOG-3076) IN SECOND HALF OF 2026 Source text: ID:nGNXbV0bkb Further company coverage: GNLX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genelux
See all newsGenelux posts wider-than-expected Q2 loss on higher R&D expenses
Genelux Corp expected to post a loss of 20 cents a share - Earnings Preview
Genelux Q1 net loss widens, misses analyst expectations
Brief: Genelux Corporation Announces Pricing Of $20.0 Million Underwritten Public Offering Of Common Stock
Brief: Genelux Corporation Announces Proposed Public Offering of Common Stock